“Should anti-CGRP monoclonal antibodies always be the drug of first choice for migraine prophylaxis in Brazil? - a pharmacoeconomic study” (2024) Headache Medicine, 15(3), pp. 170–174. doi:10.48208/HeadacheMed.2024.34.